Veracyte stock analysis (VCYT)

Research Veracyte's valuation, financial performance, ownership activity and company fundamentals.

Key company data

• Latest recorded price: $59.78 on 2026-07-30
• Market capitalization: $4.45B
• Price-to-earnings ratio: 51.58
• Analyst target price: $56.55
• Sector: Biotechnology

About Veracyte

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

Data last updated: 2026-07-31